Albert Bullich-Cortes
Barcelona, CT, Spain
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 15 publications
Prognostic value of measurable residual disease (MRD) for venetoclax in combination with hypomethylating agents in patients diagnosed with acute myeloid leukemia: validation of the ELN-2021 MRD recommendations.
Journal: Blood cancer journal
Published: February 11, 2025
Hypomethylating agents plus venetoclax for high-risk MDS and CMML as bridge therapy to transplant: a GESMD study.
Journal: Experimental hematology & oncology
Published: December 26, 2024
Measurable Residual Disease in UBTF-TD Adult Acute Myeloid Leukemia.
Journal: European journal of haematology
Published: November 20, 2024
At-Home Care Program for Acute Myeloid Leukemia Induction Phase in Patients Treated with Venetoclax-Based Low-Intensity Regimens.
Journal: Cancers
Published: November 04, 2024
Clinical management of patients diagnosed with acute myeloid leukemia treated with venetoclax in combination with hypomethylating agents after achieving a response: a real-life study.
Journal: Annals of hematology
Published: May 31, 2024
Allogeneic hematopoietic cell transplantation with sequential conditioning regimen in relapsed refractory acute myeloid leukemia.
Journal: Bone marrow transplantation
Published: March 17, 2024
Evaluation of European LeukemiaNet 2022 risk classification in patients undergoing allogeneic haematopoietic stem cell transplantation for acute myeloid leukaemia: Identification of a very poor prognosis genetic group.
Journal: British journal of haematology
Published: March 12, 2024
Chronic myelomonocytic leukemia with NPM1 mutation or acute myeloid leukemia?
Journal: The oncologist
Published: December 09, 2023
Characteristics and long-term outcome in a large series of chronic myelomonocytic leukaemia patients including 104 formerly referred to as oligomonocytic.
Journal: British journal of haematology
Published: August 10, 2023
Last Updated: 09/26/2026